{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:15:41Z","timestamp":1774278941446,"version":"3.50.1"},"update-to":[{"DOI":"10.1016\/j.antiviral.2017.03.017","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000}}],"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001261","name":"NPF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.antiviral.2017.03.017","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T16:20:52Z","timestamp":1490631652000},"page":"185-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In\u00a0vitro and in\u00a0vivo results"],"prefix":"10.1016","volume":"142","author":[{"given":"Nataliia V.","family":"Petrova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra G.","family":"Emelyanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeniy A.","family":"Gorbunov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross P.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Aniscenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-6110","authenticated-orcid":false,"given":"Leila","family":"Gogsadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9862-2147","authenticated-orcid":false,"given":"Eteri","family":"Bakhsoliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musa R.","family":"Khaitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-9200","authenticated-orcid":false,"given":"Sebastian L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey A.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg I.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.03.017_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.03.017_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nm1713","article-title":"Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation","volume":"14","author":"Bartlett","year":"2008","journal-title":"Nat. Med."},{"issue":"256","key":"10.1016\/j.antiviral.2017.03.017_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009124","article-title":"Rhinovirus induced IL-25 in asthma exacerbation drives type-2 immunity and allergic pulmonary inflammation","volume":"6","author":"Beale","year":"2014","journal-title":"Sci. Trans. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0753-3322(99)80006-7","article-title":"The 2-5A system in viral infection and apoptosis","volume":"52","author":"Castelli","year":"1998","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.antiviral.2017.03.017_bib5","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.117.5.1482","article-title":"The role of nuclear factor-kappa B in pulmonary diseases","volume":"117","author":"Christman","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.antiviral.2017.03.017_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm1462","article-title":"Role of deficient type III interferon-lambda production in asthma exacerbations","volume":"12","author":"Contoli","year":"2006","journal-title":"Nat. Med."},{"issue":"26","key":"10.1016\/j.antiviral.2017.03.017_bib7","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differently regulated by interferon alfa or beta or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.antiviral.2017.03.017_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.coph.2013.04.010","article-title":"Anti-viral agents: potential utility in exacerbations of asthma","volume":"13","author":"Dhariwal","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2017.03.017_bib9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/bmj.315.7112.858","article-title":"Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial","volume":"315","author":"Doull","year":"1997","journal-title":"Bmj"},{"key":"10.1016\/j.antiviral.2017.03.017_bib10","first-page":"304","article-title":"Effect of released-active antibodies to CD4-receptor on lck-kinase level in culture of peripheral blood mononuclear cells","volume":"162","author":"Emelyanova","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib11","first-page":"54","article-title":"The phenomenon of release activity and the hypothesis of \u201cspatial\u201d homeostasis","volume":"44","author":"Epstein","year":"2013","journal-title":"Usp. Fiziol. Nauk."},{"key":"10.1016\/j.antiviral.2017.03.017_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10517-009-0705-x","article-title":"Efficiency of interferon inductor anaferon (pediatric formulation) in prophylaxis of acute respiratory infections in sickly children","author":"Erman","year":"2009","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib13","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1164\/ajrccm.162.6.2003019","article-title":"Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection","volume":"162","author":"Gern","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.antiviral.2017.03.017_bib14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1073\/pnas.91.5.1839","article-title":"Members of low density lipoprotein receptor family mediate cells entry of the minor group common cold virus","volume":"91","author":"Hofer","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7 Suppl.\u00a0l","key":"10.1016\/j.antiviral.2017.03.017_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/irv.12173","article-title":"Advances in antivirals for non-influenza respiratory virus infections","volume":"3","author":"Hyden","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2017.03.017_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1067\/mai.2000.106376","article-title":"The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils","volume":"105","author":"Jarjour","year":"2000","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2017.03.017_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaci.2004.09.025","article-title":"The September epidemic of asthma exacerbations in children: a search for etiology","volume":"115","author":"Johnston","year":"2005","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2017.03.017_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10517-009-0703-z","article-title":"Anaferon (pediatric formulation) in prophylactics of acute respiratory viral infection in children","volume":"148","author":"Kudin","year":"2009","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/15216540600838232","article-title":"RNase L: its biological roles and regulation","volume":"58","author":"Liang","year":"2006","journal-title":"IUBMB Life"},{"key":"10.1016\/j.antiviral.2017.03.017_bib20","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(03)14685-5","article-title":"Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial","volume":"362","author":"Oommen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.03.017_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1398-9995.2007.01341.x","article-title":"Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document","volume":"62","author":"Papadopoulos","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.antiviral.2017.03.017_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199711133372001","article-title":"Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group","volume":"337","author":"Pauwels","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(03)12891-7","article-title":"Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial","volume":"361","author":"Pauwels","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.03.017_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2016.09.002","article-title":"Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial","volume":"51","author":"Rafalsky","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.017_bib26","first-page":"7","article-title":"Antiviral activity of oral ultralow doses of antibodies to gamma-interferon: experimental study of influenza infection in mice","volume":"49","author":"Sergeev","year":"2004","journal-title":"Antibiot. Khimioter"},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.017_bib27","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/JVI.71.6.4736-4743.1997","article-title":"Coxacievirus A21 binds to decay accelerating factor but requires intercellular adhesion molecule 1 for cell entry","volume":"71","author":"Shafren","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.03.017_bib28","first-page":"144","article-title":"Novel possibilities for the treatment of the respiratory-syncytial viral infection: the results of the preclinical study of ergoferon","volume":"33","author":"Shilovsky","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.antiviral.2017.03.017_bib29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10517-009-0378-5","article-title":"Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection","volume":"146","author":"Shishkina","year":"2008","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2017.03.017_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/288098a0","article-title":"Interferon-dependent induction of mRNA activity for (2'-5')oligo-isoadenylate synthetase","volume":"288","author":"Shulman","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.03.017_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0676.1993.tb00640.x","article-title":"Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C","volume":"13","author":"Solinas","year":"1993","journal-title":"Liver"},{"issue":"11","key":"10.1016\/j.antiviral.2017.03.017_bib32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3345\/kjp.2016.59.11.432","article-title":"Rhinovirus and childhood asthma: an update","volume":"59","author":"Song","year":"2016","journal-title":"Korean. J. Pediatr."},{"key":"10.1016\/j.antiviral.2017.03.017_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/rr40","article-title":"Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists","volume":"2","author":"Steinke","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.antiviral.2017.03.017_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.antiviral.2011.11.018","article-title":"Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice","volume":"93","author":"Tarasov","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.03.017_bib36","doi-asserted-by":"crossref","first-page":"e1003520","DOI":"10.1371\/journal.ppat.1003520","article-title":"An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation","volume":"9","author":"Traub","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2017.03.017_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/00006454-199011000-00011","article-title":"The role of neutrophils in the pathogenesis of rhinovirus infections","volume":"9","author":"Turner","year":"1990","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2017.03.017_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1359-6446(04)03239-8","article-title":"Respiratory infections and asthma: current treatment strategies","volume":"9","author":"Weinberger","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2017.03.017_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1067\/mai.2001.112262","article-title":"The health economics of asthma and rhinitis. I. Assessing the economic impact","volume":"107","author":"Weiss","year":"2001","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2017.03.017_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1440-1843.2010.01897.x","article-title":"Persistence of rhinovirus RNA and IP-10 gene expression after acute asthma","volume":"16","author":"Wood","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.antiviral.2017.03.017_bib41","first-page":"17","article-title":"Immunotropic properties of anaferon and anaferon pediatric","volume":"58","author":"Zhavbert","year":"2013","journal-title":"Antibiot. Khimioter"},{"key":"10.1016\/j.antiviral.2017.03.017_bib42","first-page":"40","article-title":"Anti-inflammatory and anti-allergic features of antibodies to histamine in release-active form: review of experimental and clinical researches","volume":"1","author":"Zhavbert","year":"2014","journal-title":"Det. Infektsii"},{"key":"10.1016\/j.antiviral.2017.03.017_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI118431","article-title":"Rhinovirus stimulation of interleukin-6 in\u00a0vivo and in\u00a0vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation","volume":"97","author":"Zhu","year":"1996","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.antiviral.2017.03.017_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1378\/chest.13-1567","article-title":"Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma","volume":"145","author":"Zhu","year":"2014","journal-title":"Chest"}],"updated-by":[{"DOI":"10.1016\/j.antiviral.2019.02.010","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"record-id":"20146"},{"DOI":"10.1016\/j.antiviral.2017.03.017","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000}},{"DOI":"10.1016\/j.antiviral.2019.02.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000}}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T12:14:56Z","timestamp":1601813696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216306465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":43,"alternative-id":["S0166354216306465"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.017","relation":{"retraction":[{"id-type":"doi","id":"10.1016\/j.antiviral.2017.03.017","asserted-by":"object"}],"erratum":[{"id-type":"doi","id":"10.1016\/j.antiviral.2019.02.010","asserted-by":"object"}]},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In\u00a0vitro and in\u00a0vivo results","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}